Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090521 | 0.91 | FAAH (0.50) | GBA1FAAHPOLBCCR3 | |
| SCHEMBL4258936 | 0.77 | KDM4E (0.44) | — | |
| SCHEMBL2285371 | 0.75 | CALM1 (0.41) | GBA1CALM1 | |
| SCHEMBL6916462 | 0.73 | GBA1 (0.43) | GBA1POLBCCR3CALM1 | |
| SCHEMBL9150 | 0.73 | TMEM97 (0.44) | GBA1FAAHPOLB | |
| SCHEMBL10956979 | 0.71 | NOS1 (0.37) | GBA1 | |
| SCHEMBL8998 | 0.70 | FAAH (0.43) | GBA1FAAHPOLBCCR3 | |
| SCHEMBL10952260 | 0.70 | TP53 (0.39) | GBA1CALM1 | |
| SCHEMBL28090 | 0.69 | POLB (0.44) | GBA1FAAHPOLBCCR3 | |
| SCHEMBL228875 | 0.69 | POLB (0.44) | GBA1FAAHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118863-A | 9-Phenanthreneamide derivative and preparation method and application thereof | 安徽中医药大学 | 2024-12-13 | — | — | CN | claimed |
| CN-118076647-A | Photohardenable composition and method for forming an object in the volume of the photohardenable composition | 二次3D股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117645607-A | Electroluminescent material and application thereof | 北京燕化集联光电技术有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-109503547-B | Process for preparing benzodithiolane derivatives | 江苏师范大学 | 2021-03-16 | — | — | CN | claimed |
| US-20210033886-A1 | LENS FOR SPECTACLES AND SPECTACLES | FUJIFILM CORPORATION (JP) | 2021-02-04 | — | — | US | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| US-20070117041-A1 | Photosensitive coating for enhancing a contrast of a photolithographic exposure | INFINEON TECHNOLOGIES AG (DE) | 2007-05-24 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-03-26 | — | — | US | disclosed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-1306373-A1 | 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002076177-A2 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002066443-A2 | 2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-29 | — | — | WO | disclosed |
| US-6369098-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-.GAMMA. (PPAR.GAMMA.) AND/OR PPAR.ALPHA TREATMENT OF ENDOCRINE, SKIN, CARDIOVASCULAR, IMMUNOLOGICAL, NEUROLOGICAL, NEUROPSYCHIATRIC, NEOPLASTIC AND CHRONIC VIRAL DISEASES OF VARIOUS ORGANS | BETHESDA PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2001025226-A1 | DITHIOLANE DERIVATIVES | BETHESDA PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | GBA1 2136/4885FAAH 660/4885POLB 4248/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | GBA1 292/4885FAAH 138/4885POLB 1870/4885 |
| US-20260083735-A1 | ABHD6 ANTAGONIST | ABHD6, ABHD16A, ABHD12 | GBA1 494/4885FAAH 352/4885POLB 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.